TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05391971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: At the C6 level, a total of 7cc of 0.5% bupivacaine will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of 0.5% bupivacaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: At the C6 level, a total of 7cc of saline control will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of saline control.
Study: NCT05609526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Therapy
Description: 6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Therapy
Description: 6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Therapy
Description: 6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time per day will be 30 minutes.
Study: NCT06310135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtered Eyewear
Description: Filtered binocular viewing condition will be produced by eyeglasses frames with orange-tinted blue-blocking filter, eliminating all optical radiation for wavelengths shorter than 540 nm. For the filtered monocular condition, only the lens on the eyeglasses frame on the non-dominant eye will be tinted with the blue-blocking filter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtered Eyewear
Description: Filtered binocular viewing condition will be produced by eyeglasses frames with orange-tinted blue-blocking filter, eliminating all optical radiation for wavelengths shorter than 540 nm. For the filtered monocular condition, only the lens on the eyeglasses frame on the non-dominant eye will be tinted with the blue-blocking filter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unfiltered Eyewear
Description: For the unfiltered binocular, the subjects will wear transparent eyeglasses frames with no optical power. Unfiltered monocular vision will be produced by an opaque eyepatch occluding the non-dominant eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unfiltered Eyewear
Description: For the unfiltered binocular, the subjects will wear transparent eyeglasses frames with no optical power. Unfiltered monocular vision will be produced by an opaque eyepatch occluding the non-dominant eye.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Filters
Description: Dim lights with no filters.
Study: NCT05788198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: The intervention will be modelled based on the most frequently reported patient, family physician and specialist barriers in depression management. In this project, multiple interventions aiming to tackle these barriers will be set up, with the WHO Framework on Integrated People-Centred Health Services (IPCHS) serving as conceptual backbone to the study (Table 1). The IPCHS distinguishes five interdependent strategies supporting a shift in healthcare delivery, management and funding towards universal health coverage. These strategies are:~1. empowering and engaging people and communities;~2. strengthening governance and accountability;~3. reorienting the model of care;~4. coordinating services within and across sectors;~5. creating an enabling environment.
Study: NCT05609526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time per day will be 30 minutes.
Study: NCT06520059

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration
Description: Group 1 will receive two intraosseous injections of PRP and a subsequent/synchronous intra-articular injection of PRP on the same day.~Group 2 will only receive two intra-articular injections of PRP, separated by one week.
Study: NCT05609526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calf muscle exercise training
Description: A strengthening treatment program will be applied to the calf muscles.dorsiflexors and plantar flexors will consist of static stretching exercise, isotonic resistance exercise with elastic resistance bands, heel and toe raising in both feet, followed by toe raising and lowering without raising the heel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calf muscle exercise training
Description: A strengthening treatment program will be applied to the calf muscles.dorsiflexors and plantar flexors will consist of static stretching exercise, isotonic resistance exercise with elastic resistance bands, heel and toe raising in both feet, followed by toe raising and lowering without raising the heel.
Study: NCT04698187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360 mg IV is administered Q3W.
Study: NCT06330961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: Biering-Sorensen maneuver.Participants will be in a prone position with the anterosuperior iliac spines on the edge of a stretcher. Their lower body will be strapped by the ankles and hips, with the upper body suspended. Participants will keep their trunk extended and parallel to the ground for 60 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: Biering-Sorensen maneuver.Participants will be in a prone position with the anterosuperior iliac spines on the edge of a stretcher. Their lower body will be strapped by the ankles and hips, with the upper body suspended. Participants will keep their trunk extended and parallel to the ground for 60 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: After adjusting height, pedals and backrest in a cycloergometer, there will be 20 minutes of cycling, of which 5 minutes will be a warm-up at 50-60% of maximum heart rate and 15 minutes at 60-70% of maximum heart rate. There will be a constant monitoring of heart rate and oxygen saturation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: After adjusting height, pedals and backrest in a cycloergometer, there will be 20 minutes of cycling, of which 5 minutes will be a warm-up at 50-60% of maximum heart rate and 15 minutes at 60-70% of maximum heart rate. There will be a constant monitoring of heart rate and oxygen saturation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo intervention
Description: A maneuver equivalent to Biering-Sorensen test, but with upper limb support on a level step and electromyographic monitoring to ensure minimal activation of the erector spinae. It will be explained to the participant that the aim of such an intervention is to cause electromyographic silence of the erector spinae and keep it for 1 minute.
Study: NCT02590393

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: E-cigarettes
Description: Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks.
Study: NCT05944328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: systematic and structured review of patient pharmacotherapeutic treatment plans
Description: The intervention consisted of a systematic and structured review of patient pharmacotherapeutic treatment plans to identify problems or situations of risk related to pharmacological treatments and to propose changes or improvements to optimise them. phases:~Individualised review of pharmacological treatment plans to detect drug-related problems:~Indication, Appropriateness, Effectiveness, Safety When a drug-related problem was detected according to the above criteria, the pharmacist proposed an adjustment to the pharmacotherapeutic plan. The proposals could include: discontinuation of the drug, change of drug, change to a therapeutic equivalent, initiation of treatment, change of dosage, change of frequency or intensified monitoring.~The proposals made by the pharmacist were assessed and agreed upon by a committee comprising the doctors responsible and the pharmacist. Thereafter, the consensual proposals for change were discussed with the patient.
Study: NCT06330961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo intervention
Description: A maneuver equivalent to Biering-Sorensen test, but with upper limb support on a level step and electromyographic monitoring to ensure minimal activation of the erector spinae. It will be explained to the participant that the aim of such an intervention is to cause electromyographic silence of the erector spinae and keep it for 1 minute.
Study: NCT05530629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resistance training
Description: resistance training lasts for 12 weeks, three times a week, one hour each time, and the program of resistance training in the experimental group was divided into 10 exercises: Chest press, Lat pull down, Shoulder press, Squat, Leg extension, Leg curl, Bicep curl, Triceps extension, abdominal crunches, lower back exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resistance training
Description: resistance training lasts for 12 weeks, three times a week, one hour each time, and the program of resistance training in the experimental group was divided into 10 exercises: Chest press, Lat pull down, Shoulder press, Squat, Leg extension, Leg curl, Bicep curl, Triceps extension, abdominal crunches, lower back exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resistance training
Description: resistance training lasts for 12 weeks, three times a week, one hour each time, and the program of resistance training in the experimental group was divided into 10 exercises: Chest press, Lat pull down, Shoulder press, Squat, Leg extension, Leg curl, Bicep curl, Triceps extension, abdominal crunches, lower back exercises.

Intervention type: DEVICE
Group type: OTHER
Intervention: Normal P.E. course
Description: Carry out general teaching content according to the college syllabus lasts for 12 weeks , three times a week, one hour each time, and the program of Normal P.E. course in the control group will be Physical recovery exercises, learn and practice queue formation, calisthenics, five step fists, long fist and Basic movements of Gymnastics gradually changed by week.
Study: NCT04944862

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-0159
Description: administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-0159
Description: administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: administered intravenously
Study: NCT06454266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM regimen
Description: The subjects received ORM regimen treatment every 21 days for a total of 6 cycles. The specific medication is as follows  Obutinib tablets 150mg qd d1-21 (suspended 2 days before MTX use until MTX drops to safe concentration) Rituximab 375mg/m2, d1 Methotrexate 3g/m2, d2
Study: NCT05444127

Intervention type: OTHER
Intervention: Saliva samples
Description: A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
Study: NCT05655806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline bolus then infusion
Description: half an hour before discontinuation of isoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aminophylline bolus
Description: after discontinuation of isoflurane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: given as placebo
Study: NCT06657300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP
Description: A single dose of 1 ml PRP (Vacusera) was injected into the 1st CMC joint of the first group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: A single dose of 20 mg(1ml) of methyl-prednisolone (Depo-Medrol) (complemented to 1 ml by adding 0.5 ml of saline) was injected to the 1st CMC joint of the second group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
Study: NCT06656585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual food selectivity protocol
Description: Children in the experimental group wear Oculus headsets and interact with virtual foods for 20 minutes. In the Pairing in the Kitchen phase, Oculus is removed. Two identical plates with 6 foods are placed in front of the child. The operator, seated next to the child, interacts with the food without eating it, maintaining a positive expression, and discussing non-food topics. No prompts to eat are given, and the child can leave at any time. Progress to the next phase if the child sits calmly for 30 seconds across 3 sessions.~Shaping Phase: Two identical plates are prepared. The operator comments on the food and keeps a small container of the child's favorite food visible but out of reach. Any food-related behavior is reinforced with praise and the favorite food. Target behaviors are adjusted if no response occurs for 15 seconds or if negative emotions are observed. Differential reinforcement is used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional food selectivity protocol
Description: Step 1:Pairing in the Kitchen Propose enjoyable activities in the kitchen. Move to Step 2 when the child plays in the kitchen for 5 minutes over 3 consecutive sessions.~Step 2:Transition to Kitchen Two plates with 6 identical foods are placed in the kitchen. The operator engages the child in a welcome game, waiting 30 seconds for spontaneous interaction. If no response, the operator prompts the child to go to the kitchen. If the child doesn't follow within 30 seconds, the session is postponed. The operator sits next to the child and interacts with the food, without encouraging the child to eat. Progress when the child stays seated for 30 seconds without problem behavior for 3 sessions.~Step 3:Shaping Two plates are prepared, and the operator comments on the food. A visible container with the child's favorite food is used for reinforcement. Target behaviors are reinforced with praise and the favorite food. Adjust behaviors if there's no response for 15 seconds or negative emotions occur
Study: NCT06656091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simmitinib
Description: simmitinib 6mg,QD ,3 weeks on 1 week off

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: investigator's choice of chemotherapy,include docetaxel or irinotecan.
Description: docetaxel injection 75mg/m\^2,d1,every 3 weeks or ilinotecan injection 180mg/m\^2,d1,every 2 weeks
Study: NCT06656546

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tracheal Ultrasound
Description: In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. A linear transducer will be placed perpendicular to the trachea at the level of the cricoid membrane. During ETI, visualization of the ETT moving within the trachea, specifically behind the cricothyroid membrane, indicates successful intubation. In contrast, if the ETT is mistakenly placed in the esophagus, a double-lumen appearance lateral to the trachea, created by the ETT within the esophagus, suggests esophageal intubation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. Following ETI, the presence of lung sliding will be evaluated using ultrasound with the aid of a linear probe.The transducer will be placed bilaterally along the mid-axillary line, between the second and fifth intercostal spaces, in a coronal orientation. After the ETT is placed and ventilation is initiated, the movement of the visceral and parietal pleura will be assessed. The presence of sliding motion between these pleural layers during ventilation indicates successful intubation, whereas the absence of this movement suggests a failed intubation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diaphragm Ultrasound
Description: In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Curvilinear Probe (2-8 MHz) or the eSaote MyLab Seven Curvilinear Probe (1-8 MHz), will be selected based on suitability for the procedure at the time. Using a curvilinear transducer, the probe will be placed along the mid-axillary line, approximately at the seventh to ninth intercostal spaces, in a coronal orientation. The movement of the diaphragm during ventilation will be assessed over the spleen and liver. Diaphragmatic motion during ventilation indicates successful ETI, while the absence of bilateral diaphragmatic movement suggests esophageal intubation. If diaphragmatic movement is only observed on one side, it is indicative of endobronchial intubation.
Study: NCT06657209

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insulin resistance testing
Description: Steady state Plasma Glucose test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insulin resistance testing
Description: Steady state Plasma Glucose test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insulin resistance testing
Description: Steady state Plasma Glucose test

Intervention type: PROCEDURE
Group type: OTHER
Intervention: OGTT
Description: Will collect 5 blood draws during the test to measure insulin secretion
Study: NCT04774458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopic-guided cervical epidural access
Description: After identifying the target level of the cervical spine under a fluoroscopy-guided anteroposterior image, an 18-Tuohy needle is inserted through a paramedian approach after local infiltration with 1% lidocaine. When feeling a strong resistance through the needle by a ligamentum flavum, the image intensifier is rotated to 50 degrees contralateral oblique (CLO) direction. After then, the needle is advanced to just before the ventral interlaminar line in CLO view. It is subsequently advanced further until it is in the epidural space using a LOR-to-air technique. Correct epidural access is confirmed by the injection of contrast medium. After identifying epidural space in AP and CLO view without abnormal dispersion of contrast,(vascular uptake, intrathecal spreads, etc.), a 3-4ml mixture of 0.5% lidocaine with dexamethasone 5mg is injected.
Study: NCT06657209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OGTT
Description: Will collect 5 blood draws during the test to measure insulin secretion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OGTT
Description: Will collect 5 blood draws during the test to measure insulin secretion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fat biopsy
Description: Needle biopsy to gather a sample of abdominal subcutaneous fat

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat biopsy
Description: Needle biopsy to gather a sample of abdominal subcutaneous fat

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat biopsy
Description: Needle biopsy to gather a sample of abdominal subcutaneous fat

Intervention type: RADIATION
Group type: OTHER
Intervention: DXA scan
Description: Whole body DXA scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DXA scan
Description: Whole body DXA scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DXA scan
Description: Whole body DXA scan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: Abdominal MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Abdominal MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Abdominal MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 1H-MRS
Description: Spectroscopy of the abdominal region

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1H-MRS
Description: Spectroscopy of the abdominal region

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1H-MRS
Description: Spectroscopy of the abdominal region

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: 16 weeks started at 2.5mg/week and increased to 5mg/week dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: 16 weeks started at 2.5mg/week and increased to 5mg/week dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 16 weeks at a 45mg/day dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 16 weeks at a 45mg/day dose
Study: NCT06655987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unrestrained Femoral Internal Rotation (UFIR) manipulation
Description: This is the primary intervention applied to the experimental group. It involves a high-velocity, low-amplitude thrust at the greater trochanter of the affected hip, intended to improve joint mobility and potentially address neuromuscular dysfunction contributing to hip pain and weakness.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham manipulation
Description: This serves as the control intervention. It involves gentle hand placement over the affected hip\&#39;s external rotators for a brief duration. This is intended to mimic the physical contact of the UFIR manipulation without actually delivering the therapeutic thrust.
Study: NCT05636319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABO1020
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo